- Home
- BIIB vs FFIV Comparison
BIIB vs FFIV Comparison
Compare BIIB & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FFIV
- Stock Information
- Founded
- BIIB 1978
- FFIV 1996
- Country
- BIIB United States
- FFIV United States
- Employees
- BIIB N/A
- FFIV N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FFIV Computer Communications Equipment
- Sector
- BIIB Health Care
- FFIV Telecommunications
- Exchange
- BIIB Nasdaq
- FFIV Nasdaq
- Market Cap
- BIIB 18.7B
- FFIV 18.0B
- IPO Year
- BIIB 1991
- FFIV 1999
- Fundamental
- Price
- BIIB $144.56
- FFIV $330.75
- Analyst Decision
- BIIB Buy
- FFIV Hold
- Analyst Count
- BIIB 27
- FFIV 11
- Target Price
- BIIB $188.09
- FFIV $314.90
- AVG Volume (30 Days)
- BIIB 1.5M
- FFIV 392.7K
- Earning Date
- BIIB 10-29-2025
- FFIV 10-27-2025
- Dividend Yield
- BIIB N/A
- FFIV N/A
- EPS Growth
- BIIB 31.67
- FFIV 22.06
- EPS
- BIIB 10.45
- FFIV 11.34
- Revenue
- BIIB $9,997,000,000.00
- FFIV $3,024,656,000.00
- Revenue This Year
- BIIB $2.00
- FFIV $11.86
- Revenue Next Year
- BIIB N/A
- FFIV $4.03
- P/E Ratio
- BIIB $13.83
- FFIV $28.54
- Revenue Growth
- BIIB 3.36
- FFIV 8.94
- 52 Week Low
- BIIB $110.04
- FFIV $211.89
- 52 Week High
- BIIB $204.18
- FFIV $337.39
- Technical
- Relative Strength Index (RSI)
- BIIB 58.75
- FFIV 61.91
- Support Level
- BIIB $141.12
- FFIV $320.54
- Resistance Level
- BIIB $147.23
- FFIV $337.39
- Average True Range (ATR)
- BIIB 4.56
- FFIV 6.90
- MACD
- BIIB 0.11
- FFIV 0.59
- Stochastic Oscillator
- BIIB 67.64
- FFIV 81.20
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.